PCV21 A BENEFIT-RISK ASSESSMENT OF USING CYP2C19 GENOTYPE INFORMATION TO GUIDE ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
May 1, 2010, 00:00 AM
10.1016/S1098-3015(10)72741-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)72741-8/fulltext
Section Title :
Section Order :
297
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72741-8&doi=10.1016/S1098-3015(10)72741-8